Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. NK cell engagers represent a novel mechanism with the potential to address a broad range of cancers, including potential for activity in checkpoint resistant and refractory tumors, as well as other di

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

BioNTech SE

Eli Lilly

Merck

Check out these pharmaceutical stocks in the stock market today.

Top Pharmaceutical Stocks To Watch In May 2022

RBC Capital Market views Gilead Sciences Inc's (NASDAQ: GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses.  The analyst notes that the story.

Why These Analysts Are Bullish On Gilead's Q1 Earnings

Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.

Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales

Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - EVP & CFO Christi Shaw - CEO, Kite Conference Call Participants Michael Yee - Jefferies Brian Abrahams - RBC Capital Markets Geoffrey Meacham - Bank of America Merrill Lynch Robyn Karnauskas - Truist Securities Umer Raffat - Evercore ISI Colin Bristow - UBS Tyler Van Buren - Cowen and Company Gavin Scott - JPMorgan Chase & Co. Guyn Kim - Piper Sandler & Co. Evan Seigerman - BMO Capital Markets Mohit Bansal - Wells Fargo Securities Simon Baker - Redburn Operator Thank you for standing by and welcome to the Gilead Sciences First Quarter 2022 Earnings Conference Call. [Operator Instructions].

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2022 Results - Earnings Call Transcript

Gilead (GILD) delivered earnings and revenue surprises of 19.77% and 6.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Beats Q1 Earnings and Revenue Estimates

Gilead Sciences Inc on Thursday said its first-quarter revenue rose 3%, helped by increased sales of HIV drug Biktarvy and COVID-19 antiviral drug Veklury.

Gilead first quarter sales, earnings beat Street estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2022. “Gilead's performance in the first quarter reflects the strength and diversity of our business with both our HIV and oncology therapies contributing to year-over-year growth,” said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. “Biktarvy delivered strong 18% year-over-year revenue growth, and oncology sales increased by 60% yea

Gilead Sciences Announces First Quarter 2022 Financial Results

Emergent BioSolutions

Sanofi

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Gilead (GILD) Ahead of Earnings?

Gilead Sciences Inc. GILD, -0.31% has steadily expanded the use of Veklury while much of the nation's attention has shifted to the arrival of new antivirals that can be picked up at a pharmacy counter.

How Gilead is positioning its COVID-19 drug against newer antivirals like Paxlovid

Devon Energy

Honda

Manulife Financial

Rio Tinto plc Sponsored

Southern Copper

Vale S.A.

Stock markets will return less this year as interest rates rise and cause a recession, so investors should demand higher yield. The post 7 Dividend Stocks Paying Over 5% to Buy Now appeared first on InvestorPlace.

7 Dividend Stocks Paying Over 5% to Buy Now

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of pediatric patients who are older than 28 days, weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe COVID-19, including hospitalization or death. This app

Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

The Food and Drug Administration said Monday it expanded the approval of Gilead Sciences Inc.'s GILD, -0.27% Veklury to include pediatric patients between the ages of four weeks and 12 years old. (Infants must also weigh at least seven pounds.

FDA formally approves Gilead's Veklury for young children

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.

Gilead (GILD) to Report Q1 Earnings: Is a Beat in the Cards?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced findings from two studies, which provide further insights on the use of Veklury® (remdesivir) for the treatment of hospitalized and non-hospitalized patients with COVID-19. The first study is a retrospective observational analysis of the real-world treatment data from the Premier Healthcare Database consisting of 853,219 patients hospitalized with COVID-19 across the United States. This analysis found tha

Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite's FDA approved CAR T-cell therapy used to treat blood cancer. The Maryland site joins Kite's existing manufacturing facilities in Southern California and Amsterdam, Netherlands to form the largest, dedicated in-h

Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2022 financial results will be released on Thursday, April 28, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2022 financial results and will provide a business update. A live webcast will be available on the investor relations page of investors.gilead.com and will be archived there for one

Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022

Amylyx Pharmaceuticals

Biogen

bluebird bio

Bristol-Myers

TG Therapeutics

If readouts on clinical trials can impact the stocks of pharma companies, the Food and Drug Administration (FDA) decisions on whether or not specific drugs are approved can affect not only the stock price but also a company's future.

5 Key FDA Decisions Could Affect Drug Stocks

According to my DCF analysis, GILD stock has a potential upside of almost 100%. After 7 years of stalemate, Gilead Sciences may be ready to reverse its downtrend.

Gilead Sciences: The Most Undervalued Pharmaceutical Company

Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.

Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed

The Food and Drug Administration's decision on Monday to lift the partial hold on Gilead Sciences Inc.'s GILD, -0.66% magrolimab for two indications is "good news" for the company, according to RBC Capital Markets analysts. "While GILD still has much to prove around its emerging oncology franchise, we see this as a much-needed piece of good news," analysts wrote in a note to investors on Monday.

RBC: the FDA lifting the hold on Gilead's experimental cancer therapy is a 'much-need piece of good news'

The U.S. Food and Drug Administration has lifted a partial clinical hold on studies evaluating magrolimab in combination with azacitidine, Gilead Sciences Inc. said Monday.

Dow Jones Newswires: Gilead says FDA lifts partial clinical hold on MDS and AML magrolimab studies

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with azacitidine. The FDA removed the partial clinical hold after a review of the comprehensive safety data from each trial. With today's decision from the FDA, enrollment in the U.S. can resume for the studies investigating magrolimab in combin

News for Gilead Sciences Stock (GILD)